Literature DB >> 22814351

IL-12 family cytokines: immunological playmakers.

Dario A A Vignali1, Vijay K Kuchroo.   

Abstract

The interleukin 12 (IL-12) family is unique in having the only heterodimeric cytokines, including IL-12, IL-23, IL-27 and IL-35. This feature endows these cytokines with a unique set of connections and functional interactions not shared by other cytokine families. Despite sharing many structural features and molecular partners, cytokines of the IL-12 family mediate surprisingly diverse functional effects. Here we discuss the unique and unusual structural and functional characteristics of this cytokine family. We outline how cells might interpret seemingly similar cytokine signals to give rise to the diverse functional outcomes that characterize this cytokine family. We also discuss the therapeutic implications of this complexity.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22814351      PMCID: PMC4158817          DOI: 10.1038/ni.2366

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  94 in total

Review 1.  Regulation of interleukin-12 production in antigen-presenting cells.

Authors:  X Ma; G Trinchieri
Journal:  Adv Immunol       Date:  2001       Impact factor: 3.543

2.  The composition and signaling of the IL-35 receptor are unconventional.

Authors:  Lauren W Collison; Greg M Delgoffe; Clifford S Guy; Kate M Vignali; Vandana Chaturvedi; DeLisa Fairweather; Abhay R Satoskar; K Christopher Garcia; Christopher A Hunter; Charles G Drake; Peter J Murray; Dario A A Vignali
Journal:  Nat Immunol       Date:  2012-02-05       Impact factor: 25.606

3.  Interleukin-12 differentially regulates expression of IFN-gamma and interleukin-2 in human T lymphoblasts.

Authors:  H L Dickensheets; S L Freeman; R P Donnelly
Journal:  J Interferon Cytokine Res       Date:  2000-10       Impact factor: 2.607

4.  Charged residues dominate a unique interlocking topography in the heterodimeric cytokine interleukin-12.

Authors:  C Yoon; S C Johnston; J Tang; M Stahl; J F Tobin; W S Somers
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

Review 5.  Serine phosphorylation of STATs.

Authors:  T Decker; P Kovarik
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

6.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.

Authors:  B Oppmann; R Lesley; B Blom; J C Timans; Y Xu; B Hunte; F Vega; N Yu; J Wang; K Singh; F Zonin; E Vaisberg; T Churakova; M Liu; D Gorman; J Wagner; S Zurawski; Y Liu; J S Abrams; K W Moore; D Rennick; R de Waal-Malefyt; C Hannum; J F Bazan; R A Kastelein
Journal:  Immunity       Date:  2000-11       Impact factor: 31.745

Review 7.  IL-12/IL-13 axis in allergic asthma.

Authors:  M Wills-Karp
Journal:  J Allergy Clin Immunol       Date:  2001-01       Impact factor: 10.793

8.  Distinct subunit pairing criteria within the heterodimeric IL-12 cytokine family.

Authors:  Lindsay L Jones; Vandana Chaturvedi; Catherine Uyttenhove; Jacques Van Snick; Dario A A Vignali
Journal:  Mol Immunol       Date:  2012-04-07       Impact factor: 4.407

Review 9.  New directions in the basic and translational biology of interleukin-27.

Authors:  Elia D Tait Wojno; Christopher A Hunter
Journal:  Trends Immunol       Date:  2011-12-15       Impact factor: 16.687

10.  Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35.

Authors:  Maria Bettini; Ashley H Castellaw; Greig P Lennon; Amanda R Burton; Dario A A Vignali
Journal:  Diabetes       Date:  2012-03-16       Impact factor: 9.461

View more
  406 in total

1.  Interleukin-12 in patients with cancer is synthesized by peripheral helper T lymphocytes.

Authors:  Marcia A Michelin; Leticia Montes; Rosekeila S Nomelini; Douglas R Abdalla; Andre A R Aleixo; Eddie F C Murta
Journal:  Oncol Lett       Date:  2015-07-08       Impact factor: 2.967

Review 2.  Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.

Authors:  Aurelien Amiot; Laurent Peyrin-Biroulet
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

Review 3.  T Cells: Soldiers and Spies--The Surveillance and Control of Effector T Cells by Regulatory T Cells.

Authors:  Bruce M Hall
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

Review 4.  Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases.

Authors:  Charles E Egwuagu; Cheng-Rong Yu; Lin Sun; Renxi Wang
Journal:  Cytokine Growth Factor Rev       Date:  2015-07-20       Impact factor: 7.638

Review 5.  IFN-γ: A cytokine at the right time, is in the right place.

Authors:  J Daniel Burke; Howard A Young
Journal:  Semin Immunol       Date:  2019-06-17       Impact factor: 11.130

Review 6.  Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.

Authors:  Juming Yan; Mark J Smyth; Michele W L Teng
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

Review 7.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

8.  Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome.

Authors:  Robert J Shulman; Monica E Jarrett; Kevin C Cain; Elizabeth K Broussard; Margaret M Heitkemper
Journal:  J Gastroenterol       Date:  2014-01-17       Impact factor: 7.527

9.  IL-12 promotes myeloid-derived suppressor cell recruitment and bacterial persistence during Staphylococcus aureus orthopedic implant infection.

Authors:  Cortney E Heim; Debbie Vidlak; Tyler D Scherr; Curtis W Hartman; Kevin L Garvin; Tammy Kielian
Journal:  J Immunol       Date:  2015-03-11       Impact factor: 5.422

10.  Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells.

Authors:  Keunok Jung; Ji-Hee Ha; Jung-Eun Kim; Jeong-Ah Kim; Ye-Jin Kim; Chul-Ho Kim; Yong-Sung Kim
Journal:  Oncoimmunology       Date:  2018-03-06       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.